Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Launay O, Artaud C, Lachâtre M, Ait-Ahmed M, Klein J, Luong Nguyen LB, Durier C, Jansen B, Tomberger Y, Jolly N, Grossmann A, Tabbal H, Brunet J, Gransagne M, Choucha Z, Batalie D, Delgado A, Müllner M, Tschismarov R, Berghmans PJ, Martin A, Ramsauer K, Escriou N, Gerke C

Open source

DOI: 10.1016/j.ebiom.2021.103810
Published: 2022 Jan
Container: EBioMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2021.103810,
  title = {Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.},
  author = {Launay O and Artaud C and Lachâtre M and Ait-Ahmed M and Klein J and Luong Nguyen LB and Durier C and Jansen B and Tomberger Y and Jolly N and Grossmann A and Tabbal H and Brunet J and Gransagne M and Choucha Z and Batalie D and Delgado A and Müllner M and Tschismarov R and Berghmans PJ and Martin A and Ramsauer K and Escriou N and Gerke C},
  year = {2022},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2021.103810},
  url = {https://doi.org/10.1016/j.ebiom.2021.103810}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
AU  - Launay O
AU  - Artaud C
AU  - Lachâtre M
AU  - Ait-Ahmed M
AU  - Klein J
AU  - Luong Nguyen LB
AU  - Durier C
AU  - Jansen B
AU  - Tomberger Y
AU  - Jolly N
AU  - Grossmann A
AU  - Tabbal H
AU  - Brunet J
AU  - Gransagne M
AU  - Choucha Z
AU  - Batalie D
AU  - Delgado A
AU  - Müllner M
AU  - Tschismarov R
AU  - Berghmans PJ
AU  - Martin A
AU  - Ramsauer K
AU  - Escriou N
AU  - Gerke C
PY  - 2022
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2021.103810
UR  - https://doi.org/10.1016/j.ebiom.2021.103810
ER  -

APA

O, L., C, A., M, L., M, A., J, K., LB, L. N., C, D., B, J., Y, T., N, J., A, G., H, T., J, B., M, G., Z, C., D, B., A, D., M, M., R, T., PJ, B., A, M., K, R., N, E., & C, G. (2022). Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103810

Source records

pubmed · retrieved 2026-09-25T22:45:17.530Z